Phathom Pharmaceuticals Inc. Company Profile
NASDAQ: PHATHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
After hours: 7.13 0.00%
Phathom Pharmaceuticals at a glance
Phathom Pharmaceuticals Inc. (NASDAQ: PHAT) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Florham Park, NJ. Phathom Pharmaceuticals is led by Mr. Steven L. Basta M.B.A. and employs about 371 people. The company's shares have traded publicly since 2019.
At a market capitalization of $548.5 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001783183, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Phathom Pharmaceuticals do?
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Business description based on the company's public filings.
Company information
- Legal name
- Phathom Pharmaceuticals Inc.
- Ticker
- NASDAQ: PHAT
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Steven L. Basta M.B.A.
- Employees
- 371
- Headquarters
- 100 Campus Drive, Florham Park, NJ, United States
- Phone
- 877 742 8466
- Website
- phathompharma.com
- IPO year
- 2019
- Market cap
- $548.51M
- SEC CIK
- 0001783183
Companies similar to Phathom Pharmaceuticals
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ACRSAclaris Therapeutics Inc. | 3.79 | +11.47% | $557.88M | vs PHAT |
| EVOEvotec SE ADR | 1.57 | -2.48% | $557.96M | vs PHAT |
| CTMXCytomX Therapeutics Inc. | 2.47 | -3.14% | $538.21M | vs PHAT |
| BLSMBlossomHill Therapeutics Inc. | 16.88 | +1.63% | $536.53M | vs PHAT |
| OCSOculis Holding AG | 8.66 | +1.88% | $533.35M | vs PHAT |
| MNPRMonopar Therapeutics Inc. | 83.98 | +0.24% | $563.69M | vs PHAT |
| NGNENeurogene Inc. | 26.50 | +2.44% | $530.30M | vs PHAT |
| STTKShattuck Labs Inc. | 5.66 | +0.09% | $568.06M | vs PHAT |